Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Sep 2

PMID 39219510

Authors

Lora D Thomas

Einas Batarseh

Lubna Hamdan

Zaid Haddadin

Daniel Dulek

Spyros Kalams

Laura S Stewart

Anna L Stahl

Herdi Rahman

Justin Z Amarin

Haya Hayek

Michael Ison

Edgar T Overton

Steven A Pergam

Andrew J Spieker

Natasha B Halasa

Affiliations

Soon will be listed here.

Abstract

Background: Adult hematopoietic cell transplant (HCT) recipients are at high risk for influenza-related morbidity and mortality and have suboptimal influenza vaccine immune responses compared to healthy adults, particularly within 2 years of transplant.

Methods: This phase II, double-blind, multicenter randomized controlled trial compared 2 doses of high-dose trivalent (HD-TIV) to 2 doses of standard-dose quadrivalent (SD-QIV) influenza vaccine administered 1 month apart in adults 3-23 months post-allogeneic HCT. Hemagglutinin antibody inhibition (HAI) titers were measured at baseline, 4 weeks following each vaccine dose, and approximately 7 months post-second vaccination. Injection-site and systemic reactions were assessed for 7 days post-vaccination. The primary immunogenicity comparison was geometric mean HAI titer (GMT) at visit 3 (4 weeks after the second dose); we used linear mixed models to estimate adjusted GMT ratios (aGMRs) comparing HD-TIV/SD-QIV for each antigen.

Results: We randomized 124 adults; 64 received SD-QIV and 60 received HD-TIV. Following the second vaccination, HD-TIV was associated with higher GMTs compared to SD-QIV for A/H3N2 (aGMR = 2.09; 95% confidence interval [CI]: [1.19, 3.68]) and B/Victoria (aGMR = 1.61; 95% CI: [1.00, 2.58]). The increase was not statistically significant for A/H1N1 (aGMR = 1.16; 95% CI: [0.67, 2.02]). There was a trend to more injection-site reactions for HD-TIV after the second vaccination compared to SD-QIV (50% vs 33%; adjusted odds ratio [aOR] = 4.53; 95% CI: [0.71, 28.9]), whereas systemic reactions were similar between groups with both injections.

Conclusions: Adult allogeneic HCT recipients who received 2 doses of HD-TIV produced higher HAI antibody responses for A/H3N2 and B/Victoria compared with 2 doses of SD-QIV, with comparable injection-site or systemic reactions.

Citing Articles

Vaccination of Adults With Cancer: ASCO Guideline.

Kamboj M, Bohlke K, Baptiste D, Dunleavy K, Fueger A, Jones L J Clin Oncol. 2024; 42(14):1699-1721.

PMID: 38498792 PMC: 11095883. DOI: 10.1200/JCO.24.00032.

References

DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371(7):635-45. DOI: 10.1056/NEJMoa1315727. View

Haddadin Z, Krueger K, Thomas L, Overton E, Ison M, Halasa N . Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients. Am J Transplant. 2020; 21(3):938-949. DOI: 10.1111/ajt.16295. View

Greenberg D, Robertson C, Noss M, Blatter M, Biedenbender R, Decker M . Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2012; 31(5):770-6. DOI: 10.1016/j.vaccine.2012.11.074. View

Dhedin N, Krivine A, Le Corre N, Mallet A, Lioure B, Bay J . Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine. 2013; 32(5):585-91. PMC: 7115606. DOI: 10.1016/j.vaccine.2013.11.073. View

McManus M, Frangoul H, McCullers J, Wang L, OShea A, Halasa N . Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 61(5):815-20. PMC: 4310469. DOI: 10.1002/pbc.24863. View

Janssen M, Bruns A, Kuball J, Raijmakers R, van Baarle D . Vaccine Responses in Adult Hematopoietic Stem Cell Transplant Recipients: A Comprehensive Review. Cancers (Basel). 2021; 13(23). PMC: 8656479. DOI: 10.3390/cancers13236140. View

Haddadin Z, Schuster J, Spieker A, Rahman H, Blozinski A, Stewart L . Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study. Pediatrics. 2021; 148(2). PMC: 8338906. DOI: 10.1542/peds.2021-051462. View

Halasa N, Savani B, Asokan I, Kassim A, Simons R, Summers C . Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients. Biol Blood Marrow Transplant. 2015; 22(3):528-35. DOI: 10.1016/j.bbmt.2015.12.003. View

Mohty B, Bel M, Vukicevic M, Nagy M, Levrat E, Meier S . Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011; 96(6):896-904. PMC: 3105652. DOI: 10.3324/haematol.2011.040386. View

10.

Yalcin S, Kondolot M, Albayrak N, Altas A, Karacan Y, Kuskonmaz B . Serological response to influenza vaccine after hematopoetic stem cell transplantation. Ann Hematol. 2010; 89(9):913-8. DOI: 10.1007/s00277-009-0897-1. View

11.

Karras N, Weeres M, Sessions W, Xu X, DeFor T, Young J . A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2012; 19(1):109-16. PMC: 3631587. DOI: 10.1016/j.bbmt.2012.08.015. View

12.

Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P . A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis. 2017; 66(11):1698-1704. DOI: 10.1093/cid/cix1082. View

13.

Hakim H, Allison K, Van de Velde L, Tang L, Sun Y, Flynn P . Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine. 2016; 34(27):3141-3148. PMC: 4899146. DOI: 10.1016/j.vaccine.2016.04.053. View

14.

GiaQuinta S, Michaels M, McCullers J, Wang L, Fonnesbeck C, OShea A . Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant. 2014; 19(2):219-28. DOI: 10.1111/petr.12419. View

15.

Teh B, Leung V, Mordant F, Sullivan S, Joyce T, Harrison S . A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2020; 73(11):e4269-e4277. DOI: 10.1093/cid/ciaa1711. View

16.

. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep. 2010; 59(16):485-6. View

17.

Schuster J, Hamdan L, Dulek D, Kitko C, Batarseh E, Haddadin Z . Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants. N Engl J Med. 2023; 388(4):374-376. PMC: 11444755. DOI: 10.1056/NEJMc2210825. View

18.

de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K . Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2010; 96(2):307-14. PMC: 3031700. DOI: 10.3324/haematol.2010.032664. View

19.

Rubin L, Levin M, Ljungman P, Davies E, Avery R, Tomblyn M . 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):309-18. DOI: 10.1093/cid/cit816. View

20.

Natori Y, Humar A, Lipton J, Kim D, Ashton P, Hoschler K . A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017; 52(7):1016-1021. DOI: 10.1038/bmt.2017.24. View